{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"340","value":"1210"},{"groupId":"OG001","spread":"4591.1","value":"7499"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"AUC was calculated using a single compartment model.","dispersionType":"Standard Deviation","groups":[{"description":"Whole blood temsirolimus and sirolimus levels were measured by LC/MS/MS. AUC was calculated using a single compartment model.","id":"OG000","title":"Temsirolimus- Parent Drug"},{"description":"Whole blood temsirolimus and sirolimus levels were measured by LC/MS/MS. AUC was calculated using a single non- compartment model.","id":"OG001","title":"Sirolimus- Active Metabolite"}],"paramType":"MEAN","populationDescription":"Seven subjects had complete series of blood samples available for evaluation for both Temsirolimus, the parent drug and Sirolimus, the active metabolite. The analysis was per protocol. The number (N) evaluable samples is less than the number of collected samples due to inadvertent processing mishaps.","reportingStatus":"POSTED","timeFrame":"Prior to the initial dose on day 1, then 2, 6, and 24 hours post dose; prior to first dose of Cycle 2, then at 1, 2, 6, 24, 96, and 120 hours post dose in patients treated at the recommended phase 2 dose, Dose Level 4.","title":"Area Under the Curve (AUC)","type":"SECONDARY","unitOfMeasure":"ng*hr/ml"}